Cantor Fitzgerald Comments on Rezolute FY2026 Earnings

Key Points

• Cantor Fitzgerald has projected that Rezolute, Inc. will report earnings of ($0.90) per share for FY2026, slightly better than the consensus estimate of ($0.93) per share.
• Despite missing a recent EPS estimate, Rezolute has received mixed ratings from analysts, with one "strong buy," six "buy," and one "sell," and an average target price of $11.83.
• Director Young-Jin Kim recently purchased over 1.23 million shares of Rezolute stock, increasing their ownership by 17.11% at an average price of $3.25 per share.

Rezolute, Inc. (NASDAQ:RZLT - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Rezolute in a research note issued to investors on Thursday, July 24th. Cantor Fitzgerald analyst P. Stavropoulos anticipates that the company will earn ($0.90) per share for the year. The consensus estimate for Rezolute's current full-year earnings is ($0.93) per share.

A number of other research firms have also recently weighed in on RZLT. HC Wainwright reaffirmed a "buy" rating and set a $14.00 price objective on shares of Rezolute in a research report on Monday, April 28th. Wall Street Zen cut Rezolute from a "hold" rating to a "sell" rating in a report on Thursday, May 22nd. Finally, Wedbush reissued an "outperform" rating and issued a $12.00 price target on shares of Rezolute in a report on Wednesday, May 14th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $11.83.

Rezolute Trading Down 2.5%

Shares of NASDAQ RZLT traded down $0.16 during trading hours on Friday, reaching $6.22. The stock had a trading volume of 272,108 shares, compared to its average volume of 957,826. Rezolute has a fifty-two week low of $2.21 and a fifty-two week high of $6.64. The firm has a 50-day moving average of $4.64 and a 200-day moving average of $4.14. The firm has a market cap of $541.14 million, a price-to-earnings ratio of -5.39 and a beta of 1.03.

Rezolute (NASDAQ:RZLT - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.05).

Insiders Place Their Bets

In related news, Director Young-Jin Kim purchased 1,230,769 shares of the company's stock in a transaction on Friday, June 13th. The stock was bought at an average price of $3.25 per share, with a total value of $3,999,999.25. Following the completion of the transaction, the director owned 8,423,386 shares of the company's stock, valued at approximately $27,376,004.50. This represents a 17.11% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders acquired a total of 1,241,345 shares of company stock worth $4,041,196 over the last ninety days. Company insiders own 18.39% of the company's stock.

Hedge Funds Weigh In On Rezolute

Hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC boosted its holdings in Rezolute by 10.9% in the fourth quarter. Nantahala Capital Management LLC now owns 2,857,982 shares of the company's stock valued at $14,004,000 after acquiring an additional 280,861 shares during the last quarter. Adage Capital Partners GP L.L.C. boosted its holdings in Rezolute by 699.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 2,525,883 shares of the company's stock valued at $12,377,000 after acquiring an additional 2,210,038 shares during the last quarter. Affinity Asset Advisors LLC boosted its holdings in Rezolute by 7.9% in the first quarter. Affinity Asset Advisors LLC now owns 1,700,000 shares of the company's stock valued at $4,930,000 after acquiring an additional 125,000 shares during the last quarter. Woodline Partners LP boosted its holdings in Rezolute by 2,817.1% in the fourth quarter. Woodline Partners LP now owns 1,089,345 shares of the company's stock valued at $5,338,000 after acquiring an additional 1,052,002 shares during the last quarter. Finally, Susquehanna International Group LLP boosted its holdings in Rezolute by 749.0% in the fourth quarter. Susquehanna International Group LLP now owns 893,601 shares of the company's stock valued at $4,379,000 after acquiring an additional 788,349 shares during the last quarter. Hedge funds and other institutional investors own 82.97% of the company's stock.

Rezolute Company Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.